RxDoctor Payments Data

Melvin Khaw, MD

Internal Medicine · Encino, CANPI 1487624045

Payments from drug & device makers

$467in general payments, 2019–2025

Across 23 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$141
  • Novo Nordisk$84
  • Johnson & Johnson$58
  • AstraZeneca$46
  • Teva Pharmaceuticals USA, Inc.$31
  • Abbott$23
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$467100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$467 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$285,971
Medicare patients
321
Services billed
8,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab74$73,783
EliquisApixaban51$43,761
OzempicSemaglutide31$39,787
MounjaroTirzepatide35$33,247
Praluent PenAlirocumab29$20,029
MyrbetriqMirabegron16$16,069
EntrestoSacubitril/Valsartan16$14,717
Lagevrio (Eua)Molnupiravir30$13,652
JardianceEmpagliflozin16$13,185
Breo ElliptaFluticasone/Vilanterol16$7,303
SynthroidLevothyroxine Sodium88$6,846
Arnuity ElliptaFluticasone Furoate11$4,412
Rosuvastatin Calcium208$2,948
Atorvastatin Calcium341$2,735
Olmesartan Medoxomil65$2,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$84$39,78731 claims
MerckLagevrio (Eua)$141$13,65230 claims
Boehringer IngelheimJardiance$16$13,18516 claims
AbbVieSynthroid$18$6,84688 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →